Literature DB >> 35767292

Brain Wellness "Spas"-Anticipating the Off-label Promotion of Psychedelics.

Anna Wexler1, Dominic Sisti1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2022        PMID： 35767292      PMCID： PMC9357212          DOI： 10.1001/jamapsychiatry.2022.1619

Source DB:  PubMed          Journal:  JAMA Psychiatry        ISSN： 2168-622X            Impact factor:   25.911


× No keyword cloud information.
  8 in total

1.  Neuroenhancement for sale: assessing the website claims of neurofeedback providers in the United States.

Authors:  Anna Wexler; Ashwini Nagappan; Deena Kopyto; Rebekah Choi
Journal:  J Cogn Enhanc       Date:  2020-04-21

2.  Toward Risk-Benefit Assessments in Psychedelic- and MDMA-Assisted Therapies.

Authors:  Mazdak M Bradberry; Natalie Gukasyan; Charles L Raison
Journal:  JAMA Psychiatry       Date:  2022-06-01       Impact factor: 25.911

Review 3.  Proceed with caution: off-label ketamine treatment for major depressive disorder.

Authors:  Dominic Sisti; Andrea G Segal; Michael E Thase
Journal:  Curr Psychiatry Rep       Date:  2014-12       Impact factor: 5.285

Review 4.  Ethical and Legal Considerations of Alternative Neurotherapies.

Authors:  Ashwini Nagappan; Louiza Kalokairinou; Anna Wexler
Journal:  AJOB Neurosci       Date:  2021-03-24

5.  The Rapid Rise in Investment in Psychedelics-Cart Before the Horse.

Authors:  Joshua Phelps; Ravi N Shah; Jeffrey A Lieberman
Journal:  JAMA Psychiatry       Date:  2022-03-01       Impact factor: 21.596

6.  Off-Label Promotion of Transcranial Magnetic Stimulation on Provider Websites.

Authors:  Anna Wexler; Ashwini Nagappan; Deena Kopyto; Emiliano Santarnecchi; Alvaro Pascual-Leone
Journal:  Brain Stimul       Date:  2021-04-23       Impact factor: 8.955

Review 7.  Psychedelics and Psychedelic-Assisted Psychotherapy.

Authors:  Collin M Reiff; Elon E Richman; Charles B Nemeroff; Linda L Carpenter; Alik S Widge; Carolyn I Rodriguez; Ned H Kalin; William M McDonald
Journal:  Am J Psychiatry       Date:  2020-02-26       Impact factor: 18.112

8.  MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study.

Authors:  Jennifer M Mitchell; Michael Bogenschutz; Alia Lilienstein; Charlotte Harrison; Sarah Kleiman; Kelly Parker-Guilbert; Marcela Ot'alora G; Wael Garas; Casey Paleos; Ingmar Gorman; Christopher Nicholas; Michael Mithoefer; Shannon Carlin; Bruce Poulter; Ann Mithoefer; Sylvestre Quevedo; Gregory Wells; Sukhpreet S Klaire; Bessel van der Kolk; Keren Tzarfaty; Revital Amiaz; Ray Worthy; Scott Shannon; Joshua D Woolley; Cole Marta; Yevgeniy Gelfand; Emma Hapke; Simon Amar; Yair Wallach; Randall Brown; Scott Hamilton; Julie B Wang; Allison Coker; Rebecca Matthews; Alberdina de Boer; Berra Yazar-Klosinski; Amy Emerson; Rick Doblin
Journal:  Nat Med       Date:  2021-05-10       Impact factor: 53.440
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.